Monte Rosa Therapeutics, Inc. Debt Securities, Available-for-sale, Unrealized Loss
Monte Rosa Therapeutics, Inc. (GLUE) reported Debt Securities, Available-for-sale, Unrealized Loss of $97.00 thousand for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2025-08-07
- Monte Rosa Therapeutics, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-06-30 was $97.00K, a 708.33% increase year-over-year.
- Monte Rosa Therapeutics, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-03-31 was $21.00K, a 425.00% increase year-over-year.
- Monte Rosa Therapeutics, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2024-09-30 was $311.00K, a 81.87% increase year-over-year.
- Monte Rosa Therapeutics, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2024-06-30 was $12.00K, a 95.40% decline year-over-year.
- Monte Rosa Therapeutics, Inc. debt securities, available-for-sale, unrealized loss for fiscal 2024 was $170.00K, a 57.18% decline from fiscal 2023.
- Monte Rosa Therapeutics, Inc. debt securities, available-for-sale, unrealized loss for fiscal 2023 was $397.00K, a 11.58% decline from fiscal 2022.
- Monte Rosa Therapeutics, Inc. debt securities, available-for-sale, unrealized loss for fiscal 2022 was $449.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month | Debt Securities, Available-for-sale, Unrealized Loss 9 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|---|---|---|
| 2025-06-30 | $97.00K 10-Q · filed 2025-08-07 | $118.00K 10-Q · filed 2025-08-07 | ||
| 2025-03-31 | $21.00K 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $170.00K 10-K · filed 2025-03-20 | |||
| 2024-09-30 | $311.00K 10-Q · filed 2024-11-07 | $323.00K derived: sum of 2 quarters · filed 2025-08-07 | $327.00K derived: sum of 3 quarters · filed 2025-08-07 | |
| 2024-06-30 | $12.00K 10-Q · filed 2025-08-07 | $16.00K 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $4.00K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $397.00K 10-K · filed 2025-03-20 | |||
| 2023-09-30 | $171.00K 10-Q · filed 2024-11-07 | $432.00K derived: sum of 2 quarters · filed 2024-11-07 | $777.00K derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $261.00K 10-Q · filed 2024-11-07 | $606.00K derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $345.00K 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $449.00K 10-K · filed 2024-03-14 | |||
| 2022-09-30 | $176.00K 10-Q · filed 2023-11-09 | $534.00K derived: sum of 2 quarters · filed 2023-11-09 | $680.00K derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $358.00K 10-Q · filed 2023-11-09 | $504.00K derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $146.00K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |